Regeneron’s revenues jump on aflibercept sales

Aflibercept brought in $831 million in U.S. sales in the second quarter, a 27% increase that topped analysts’ forecasts of $812 million.

Net sales outside the United States increased 44% to $486 million compared with the same period a year earlier.

The blockbuster anti-VEGF therapy propelled Regeneron’s revenues to $1.213 billion, up from $999 million in the second quarter of 2015, but about 2% below consensus estimates.

Aflibercept reportedly holds a 37% share of the anti-VEGF market, while ranibizumab has 19% of the pie, while bevacizumab leads with 44%. However, Regeneron’s commercial EVP Bob Terifay warned investors on the quarterly conference call that increased direct-to-physician financial incentives from the manufacturer and group purchasing organizations may turn favor to ranibizumab and bevacizumab.